1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Clostridium Infections – Pipeline Review, H1 2013

Clostridium Infections – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 134 pages

Clostridium Infections – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Clostridium Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Infections. Clostridium Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Clostridium Infections.
- A review of the Clostridium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Clostridium Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Clostridium Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Clostridium Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Clostridium Infections - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Clostridium Infections Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Clostridium Infections 11
Clostridium Infections Therapeutics under Development by Companies 13
Clostridium Infections Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Clostridium Infections Therapeutics - Products under Development by Companies 22
Clostridium Infections Therapeutics - Products under Investigation by Universities/Institutes 25
Companies Involved in Clostridium Infections Therapeutics Development 26
Sequella, Inc. 26
MedImmune LLC 27
Merck and Co., Inc. 28
Emergent BioSolutions Inc. 29
Cangene Corporation 30
ACE BioSciences A/S 31
Nanotherapeutics, Inc. 32
Novartis AG 33
Actelion Ltd 34
Cubist Pharmaceuticals, Inc. 35
ViroPharma Incorporated 36
Optimer Pharmaceuticals, Inc. 37
Intercell AG 38
Oragenics, Inc. 39
XOMA Ltd. 40
Immuron Limited 41
Summit Corporation plc 42
e-Therapeutics plc 43
ActogeniX NV 44
Novacta Biosystems Limited 45
ImmunoBiology Limited 46
Aquapharm Biodiscovery Limited 47
Osel Inc. 48
AlphaVax, Inc. 49
Microbiotix, Inc. 50
DynPort Vaccine Company LLC 51
Sorrento Therapeutics, Inc. 52
Molecular Targeting Technologies, Inc. 53
Clostridium Infections - Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Combination Products 55
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 60
surotomycin - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
fidaxomicin - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
SQ-109 - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
ACAM-Cdiff - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
Recombinant Botulinum Vaccine (rBOT) - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
MU-1140 - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
AVX-13616 - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
Botulinum Toxin Vaccine - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
oritavancin disphosphate - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
SQ-641 - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
ACE-820 - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
ETX-1153c - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
NVB-302 - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
(actoxumab + bezlotoxumab) - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
XOMA-3AB - Drug Profile 78
Product Description 78
Mechanism of Action 78
RandD Progress 78
SMT-19969 - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
ramoplanin - Drug Profile 80
Product Description 80
Mechanism of Action 80
RandD Progress 80
VP-20621 - Drug Profile 81
Product Description 81
Mechanism of Action 81
RandD Progress 81
MIYA-BM - Drug Profile 83
Product Description 83
Mechanism of Action 83
RandD Progress 83
Botulism Antitoxin Heptavalent - Drug Profile 84
Product Description 84
Mechanism of Action 84
RandD Progress 84
Clostridium Difficile Antibodies - Drug Profile 86
Product Description 86
Mechanism of Action 86
RandD Progress 86
cadazolid - Drug Profile 87
Product Description 87
Mechanism of Action 87
RandD Progress 87
IC-84 - Drug Profile 88
Product Description 88
Mechanism of Action 88
RandD Progress 88
LFF-571 - Drug Profile 90
Product Description 90
Mechanism of Action 90
RandD Progress 90
Recombinant Botulinum Vaccine - Drug Profile 92
Product Description 92
Mechanism of Action 92
RandD Progress 92
IMM-308 - Drug Profile 94
Product Description 94
Mechanism of Action 94
RandD Progress 94
MGB-BP-3 Oral - Drug Profile 95
Product Description 95
Mechanism of Action 95
RandD Progress 95
amifampridine - Drug Profile 97
Product Description 97
Mechanism of Action 97
RandD Progress 97
SMT-21829 - Drug Profile 98
Product Description 98
Mechanism of Action 98
RandD Progress 98
Botulinum Toxin Vaccine - Drug Profile 99
Product Description 99
Mechanism of Action 99
RandD Progress 99
ActoBiotics For Clostridium Difficile Enteropathy - Drug Profile 100
Product Description 100
Mechanism of Action 100
RandD Progress 100
AQP-182 - Drug Profile 101
Product Description 101
Mechanism of Action 101
RandD Progress 101
MBX-500 - Drug Profile 102
Product Description 102
Mechanism of Action 102
RandD Progress 102
MU-1140-S - Drug Profile 103
Product Description 103
Mechanism of Action 103
RandD Progress 103
Drugs Targeting BoNT/A LC - Drug Profile 105
Product Description 105
Mechanism of Action 105
RandD Progress 105
AKT-10081 - Drug Profile 106
Product Description 106
Mechanism of Action 106
RandD Progress 106
cathelicidin - Drug Profile 107
Product Description 107
Mechanism of Action 107
RandD Progress 107
Clostridium Difficile Program - Drug Profile 108
Product Description 108
Mechanism of Action 108
RandD Progress 108
Tetramic Acid Analogs - Drug Profile 109
Product Description 109
Mechanism of Action 109
RandD Progress 109
Clostridium Infections Therapeutics - Drug Profile Updates 110
Clostridium Infections Therapeutics - Dormant Products 125
Clostridium Infections - Product Development Milestones 126
Featured News and Press Releases 126
Nov 01, 2012: Optimer Initiates Phase IIIb Clinical Trial Of Dificid For Prevention Of Clostridium Difficile-associated Diarrhea In Bone Marrow Transplant Patients 126
Oct 31, 2012: Summit Initiates Phase I Trial Of Oral Antibiotic SMT 19969 For Treatment Of Clostridium Infections 127
Oct 22, 2012: Summit Receives Upto £4.0m Award From Wellcome Trust To Support C. Difficile Antibiotic 127
Oct 15, 2012: Optimer Pharma Announces Presentation Of New Research Findings For Dificid Tablets At IDWeek 2012 128
Oct 02, 2012: Optimer Pharma Introduces Strategic Initiative To Further Facilitate Patient Access To Dificid 128
Sep 27, 2012: AvidBiotics Receives SBIR Grant For Avidocin Antibacterial Proteins Against Clostridium Difficile 129
Sep 25, 2012: Summit Receives Regulatory Approval To Commence Phase I Clinical Trial Of Selective Antibiotic For Treatment Of C. Difficile Infections 130
Sep 06, 2012: Summit Updates Corporate Strategy To Focus On Development Of Clostridium Difficile Program 130
Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CB-315 At ICAAC 2012 131
Aug 06, 2012: Aquapharm Biodiscovery Discovers New Antibiotic Compound 131
Appendix 133
Methodology 133
Coverage 133
Secondary Research 133
Primary Research 133
Expert Panel Validation 133
Contact Us 134
Disclaimer 134



List of Tables

Number of Products Under Development for Clostridium Infections, H1 2013 11
Products under Development for Clostridium Infections - Comparative Analysis, H1 2013 12
Number of Products under Development by Companies, H1 2013 14
Number of Products under Development by Companies, H1 2013 (Contd..1) 15
Number of Products under Development by Companies, H1 2013 (Contd..2) 16
Number of Products under Investigation by Universities/Institutes, H1 2013 17
Comparative Analysis by Late Stage Development, H1 2013 18
Comparative Analysis by Mid Clinical Stage Development, H1 2013 19
Comparative Analysis by Early Clinical Stage Development, H1 2013 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 21
Products under Development by Companies, H1 2013 22
Products under Development by Companies, H1 2013 (Contd..1) 23
Products under Development by Companies, H1 2013 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2013 25
Sequella, Inc., H1 2013 26
MedImmune LLC, H1 2013 27
Merck and Co., Inc., H1 2013 28
Emergent BioSolutions Inc., H1 2013 29
Cangene Corporation, H1 2013 30
ACE BioSciences A/S, H1 2013 31
Nanotherapeutics, Inc., H1 2013 32
Novartis AG, H1 2013 33
Actelion Ltd, H1 2013 34
Cubist Pharmaceuticals, Inc., H1 2013 35
ViroPharma Incorporated, H1 2013 36
Optimer Pharmaceuticals, Inc., H1 2013 37
Intercell AG, H1 2013 38
Oragenics, Inc., H1 2013 39
XOMA Ltd., H1 2013 40
Immuron Limited, H1 2013 41
Summit Corporation plc, H1 2013 42
e-Therapeutics plc, H1 2013 43
ActogeniX NV, H1 2013 44
Novacta Biosystems Limited, H1 2013 45
ImmunoBiology Limited, H1 2013 46
Aquapharm Biodiscovery Limited, H1 2013 47
Osel Inc., H1 2013 48
AlphaVax, Inc., H1 2013 49
Microbiotix, Inc., H1 2013 50
DynPort Vaccine Company LLC, H1 2013 51
Sorrento Therapeutics, Inc., H1 2013 52
Molecular Targeting Technologies, Inc., H1 2013 53
Assessment by Monotherapy Products, H1 2013 54
Assessment by Combination Products, H1 2013 55
Assessment by Stage and Route of Administration, H1 2013 57
Assessment by Stage and Molecule Type, H1 2013 59
Clostridium Infections Therapeutics - Drug Profile Updates 110
Clostridium Infections Therapeutics - Dormant Products 125



List of Figures

Number of Products under Development for Clostridium Infections, H1 2013 11
Products under Development for Clostridium Infections - Comparative Analysis, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 17
Late Stage Products, H1 2013 18
Mid Clinical Stage Products, H1 2013 19
Early Clinical Stage Products, H1 2013 20
Discovery and Pre-Clinical Stage Products, H1 2013 21
Assessment by Monotherapy Products, H1 2013 54
Assessment by Combination Products, H1 2013 55
Assessment by Route of Administration, H1 2013 56
Assessment by Stage and Route of Administration, H1 2013 57
Assessment by Molecule Type, H1 2013 58
Assessment by Stage and Molecule Type, H1 2013 59

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market and Hypertension Statistics in Asia and the US

  • November 2016
    26 pages
  • Therapy  

    Hypertension  

    Cardiovascular ...  

  • Asia  

    United States  

    Europe  

View report >

Global Eye Disease Statistics

  • November 2016
    7 pages
  • Eye Disease  

  • World  

    Tanzania  

View report >

Infectious Disease Statistics in South Africa

  • November 2016
    9 pages
  • Infectious Dise...  

  • South Africa  

    Africa  

View report >

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.